Immune System Remodelling by Prenatal Betamethasone: Effects on beta-Cells and Type 1 Diabetes
Por:
Perna-Barrull, D, Gieras, A, Rodriguez-Fernandez, S, Tolosa, E and Vives-Pi, M
Publicada:
11 ago 2020
Ahead of Print:
11 ago 2020
Resumen:
Type 1 diabetes (T1D) is a multifactorial disease of unknown aetiology. Studies focusing on environment-related prenatal changes, which might have an influence on the development of T1D, are still missing. Drugs, such as betamethasone, are used during this critical period without exploring possible effects later in life. Betamethasone can interact with the development and function of the two main players in T1D, the immune system and the pancreatic beta-cells. Short-term or persistent changes in any of these two players may influence the initiation of the autoimmune reaction against beta-cells. In this review, we focus on the ability of betamethasone to induce alterations in the immune system, impairing the recognition of autoantigens. At the same time, betamethasone affects beta-cell gene expression and apoptosis rate, reducing the danger signals that will attract unwanted attention from the immune system. These effects may synergise to hinder the autoimmune attack. In this review, we compile scattered evidence to provide a better understanding of the basic relationship between betamethasone and T1D, laying the foundation for future studies on human cohorts that will help to fully grasp the role of betamethasone in the development of T1D.
Filiaciones:
:
Autonomous Univ Barcelona, Immunol Sect, Germans Trias & Pujol Res Inst, Badalona, Spain
Gieras, A:
Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany
:
Autonomous Univ Barcelona, Immunol Sect, Germans Trias & Pujol Res Inst, Badalona, Spain
Tolosa, E:
Univ Med Ctr Hamburg Eppendorf, Dept Immunol, Hamburg, Germany
:
Autonomous Univ Barcelona, Immunol Sect, Germans Trias & Pujol Res Inst, Badalona, Spain
Green Published, gold
|